25 XP   0   0   10

Hansa Biopharma AB
Buy, Hold or Sell?

Let's analyse Hansa Biopharma AB together

PenkeI guess you are interested in Hansa Biopharma AB. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Hansa Biopharma AB. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Hansa Biopharma AB

I send you an email if I find something interesting about Hansa Biopharma AB.

Quick analysis of Hansa Biopharma AB (30 sec.)










What can you expect buying and holding a share of Hansa Biopharma AB? (30 sec.)

How much money do you get?

How much money do you get?
kr0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
kr-7.10
Expected worth in 1 year
kr-22.08
How sure are you?
17.5%

+ What do you gain per year?

Total Gains per Share
kr-14.98
Return On Investment
-53.2%

For what price can you sell your share?

Current Price per Share
kr28.14
Expected price per share
kr22.00 - kr40.50
How sure are you?
50%

1. Valuation of Hansa Biopharma AB (5 min.)




Live pricePrice per Share (EOD)

kr28.14

Intrinsic Value Per Share

kr-146.23 - kr-110.37

Total Value Per Share

kr-153.33 - kr-117.47

2. Growth of Hansa Biopharma AB (5 min.)




Is Hansa Biopharma AB growing?

Current yearPrevious yearGrowGrow %
How rich?-$34.3m$42.3m-$52m-536.9%

How much money is Hansa Biopharma AB making?

Current yearPrevious yearGrowGrow %
Making money-$19.4m-$15.5m-$3.8m-19.7%
Net Profit Margin-605.1%-551.5%--

How much money comes from the company's main activities?

3. Financial Health of Hansa Biopharma AB (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#980 / 1011

Most Revenue
#377 / 1011

Most Profit
#688 / 1011

Most Efficient
#765 / 1011

What can you expect buying and holding a share of Hansa Biopharma AB? (5 min.)

Welcome investor! Hansa Biopharma AB's management wants to use your money to grow the business. In return you get a share of Hansa Biopharma AB.

What can you expect buying and holding a share of Hansa Biopharma AB?

First you should know what it really means to hold a share of Hansa Biopharma AB. And how you can make/lose money.

Speculation

The Price per Share of Hansa Biopharma AB is kr28.14. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Hansa Biopharma AB.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Hansa Biopharma AB, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is kr-7.10. Based on the TTM, the Book Value Change Per Share is kr-3.74 per quarter. Based on the YOY, the Book Value Change Per Share is kr-1.05 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is kr0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Hansa Biopharma AB.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 kr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Share
Usd Eps-0.38-1.4%-0.37-1.3%-0.30-1.0%-0.25-0.9%-0.16-0.6%
Usd Book Value Change Per Share-0.36-1.3%-0.34-1.2%-0.10-0.3%-0.11-0.4%-0.02-0.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.36-1.3%-0.34-1.2%-0.10-0.3%-0.11-0.4%-0.02-0.1%
Usd Price Per Share2.67-3.06-4.80-9.32-10.57-
Price to Earnings Ratio-1.75--2.15--4.14--11.39--28.26-
Price-to-Total Gains Ratio-7.43--9.44--10.98--41.79--98.15-
Price to Book Ratio-4.10--7.22-6.32-5.58-15.20-
Price-to-Total Gains Ratio-7.43--9.44--10.98--41.79--98.15-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.586066
Number of shares386
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.34-0.11
Usd Total Gains Per Share-0.34-0.11
Gains per Quarter (386 shares)-132.82-40.72
Gains per Year (386 shares)-531.29-162.89
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-531-5410-163-173
20-1063-10720-326-336
30-1594-16030-489-499
40-2125-21340-652-662
50-2656-26650-814-825
60-3188-31960-977-988
70-3719-37270-1140-1151
80-4250-42580-1303-1314
90-4782-47890-1466-1477
100-5313-53200-1629-1640

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%0.041.00.00.0%
Book Value Change Per Share0.04.00.00.0%1.011.00.08.3%2.018.00.010.0%7.032.01.017.5%7.032.02.017.1%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.041.00.0%
Total Gains per Share0.04.00.00.0%1.011.00.08.3%2.018.00.010.0%7.032.01.017.5%7.032.02.017.1%

Fundamentals of Hansa Biopharma AB

About Hansa Biopharma AB

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD); AskBio to evaluate imlifidase as a pre-treatment in pompe disease; and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

Fundamental data was last updated by Penke on 2024-04-22 05:27:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Hansa Biopharma AB.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Hansa Biopharma AB earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compare Hansa Biopharma AB to the Biotechnology industry mean.
  • A Net Profit Margin of -390.5% means that kr-3.90 for each kr1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Hansa Biopharma AB:

  • The MRQ is -390.5%. The company is making a huge loss. -2
  • The TTM is -605.1%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-390.5%TTM-605.1%+214.6%
TTM-605.1%YOY-551.5%-53.5%
TTM-605.1%5Y-4,806.3%+4,201.2%
5Y-4,806.3%10Y-4,713.8%-92.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-390.5%-196.1%-194.4%
TTM-605.1%-211.9%-393.2%
YOY-551.5%-277.7%-273.8%
5Y-4,806.3%-432.9%-4,373.4%
10Y-4,713.8%-599.3%-4,114.5%
1.1.2. Return on Assets

Shows how efficient Hansa Biopharma AB is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Hansa Biopharma AB to the Biotechnology industry mean.
  • -26.3% Return on Assets means that Hansa Biopharma AB generated kr-0.26 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Hansa Biopharma AB:

  • The MRQ is -26.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -19.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-26.3%TTM-19.6%-6.7%
TTM-19.6%YOY-13.8%-5.8%
TTM-19.6%5Y-14.6%-5.0%
5Y-14.6%10Y-13.3%-1.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-26.3%-13.3%-13.0%
TTM-19.6%-12.7%-6.9%
YOY-13.8%-11.8%-2.0%
5Y-14.6%-14.0%-0.6%
10Y-13.3%-15.9%+2.6%
1.1.3. Return on Equity

Shows how efficient Hansa Biopharma AB is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Hansa Biopharma AB to the Biotechnology industry mean.
  • 0.0% Return on Equity means Hansa Biopharma AB generated kr0.00 for each kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Hansa Biopharma AB:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-34.5%+34.5%
TTM-34.5%YOY-38.5%+4.1%
TTM-34.5%5Y-24.1%-10.4%
5Y-24.1%10Y-18.9%-5.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--16.9%+16.9%
TTM-34.5%-16.0%-18.5%
YOY-38.5%-15.1%-23.4%
5Y-24.1%-19.7%-4.4%
10Y-18.9%-20.5%+1.6%

1.2. Operating Efficiency of Hansa Biopharma AB.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Hansa Biopharma AB is operating .

  • Measures how much profit Hansa Biopharma AB makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Hansa Biopharma AB to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated kr0.00  for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Hansa Biopharma AB:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-468.4%+468.4%
TTM-468.4%YOY-519.3%+50.9%
TTM-468.4%5Y-4,788.3%+4,319.8%
5Y-4,788.3%10Y-3,634.0%-1,154.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--290.9%+290.9%
TTM-468.4%-224.4%-244.0%
YOY-519.3%-288.3%-231.0%
5Y-4,788.3%-479.5%-4,308.8%
10Y-3,634.0%-625.2%-3,008.8%
1.2.2. Operating Ratio

Measures how efficient Hansa Biopharma AB is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 3.73 means that the operating costs are kr3.73 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of Hansa Biopharma AB:

  • The MRQ is 3.731. The company is inefficient in keeping operating costs low. -1
  • The TTM is 6.356. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ3.731TTM6.356-2.625
TTM6.356YOY6.081+0.276
TTM6.3565Y48.903-42.546
5Y48.90310Y47.813+1.090
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.7313.110+0.621
TTM6.3563.266+3.090
YOY6.0813.783+2.298
5Y48.9035.657+43.246
10Y47.8137.783+40.030

1.3. Liquidity of Hansa Biopharma AB.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Hansa Biopharma AB is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.55 means the company has kr2.55 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of Hansa Biopharma AB:

  • The MRQ is 2.551. The company is able to pay all its short-term debts. +1
  • The TTM is 3.191. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ2.551TTM3.191-0.639
TTM3.191YOY5.344-2.154
TTM3.1915Y7.584-4.394
5Y7.58410Y8.565-0.981
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.5513.905-1.354
TTM3.1914.212-1.021
YOY5.3445.337+0.007
5Y7.5846.062+1.522
10Y8.5656.401+2.164
1.3.2. Quick Ratio

Measures if Hansa Biopharma AB is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Hansa Biopharma AB to the Biotechnology industry mean.
  • A Quick Ratio of 2.55 means the company can pay off kr2.55 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Hansa Biopharma AB:

  • The MRQ is 2.547. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.160. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.547TTM3.160-0.614
TTM3.160YOY5.448-2.288
TTM3.1605Y9.740-6.580
5Y9.74010Y11.376-1.636
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.5473.572-1.025
TTM3.1604.001-0.841
YOY5.4485.364+0.084
5Y9.7406.009+3.731
10Y11.3766.287+5.089

1.4. Solvency of Hansa Biopharma AB.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Hansa Biopharma AB assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Hansa Biopharma AB to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.45 means that Hansa Biopharma AB assets are financed with 145.1% credit (debt) and the remaining percentage (100% - 145.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Hansa Biopharma AB:

  • The MRQ is 1.451. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.134. The company is just not able to pay all its debts by selling its assets. -1
Trends
Current periodCompared to+/- 
MRQ1.451TTM1.134+0.317
TTM1.134YOY0.626+0.508
TTM1.1345Y0.445+0.689
5Y0.44510Y0.271+0.174
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4510.336+1.115
TTM1.1340.334+0.800
YOY0.6260.271+0.355
5Y0.4450.366+0.079
10Y0.2710.389-0.118
1.4.2. Debt to Equity Ratio

Measures if Hansa Biopharma AB is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Hansa Biopharma AB to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has kr0.00 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Hansa Biopharma AB:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM1.620-1.620
TTM1.620YOY2.012-0.392
TTM1.6205Y0.841+0.779
5Y0.84110Y0.476+0.365
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.382-0.382
TTM1.6200.397+1.223
YOY2.0120.341+1.671
5Y0.8410.432+0.409
10Y0.4760.465+0.011

2. Market Valuation of Hansa Biopharma AB

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every kr1 in earnings Hansa Biopharma AB generates.

  • Above 15 is considered overpriced but always compare Hansa Biopharma AB to the Biotechnology industry mean.
  • A PE ratio of -1.75 means the investor is paying kr-1.75 for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Hansa Biopharma AB:

  • The EOD is -1.695. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.753. Based on the earnings, the company is expensive. -2
  • The TTM is -2.153. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.695MRQ-1.753+0.058
MRQ-1.753TTM-2.153+0.400
TTM-2.153YOY-4.145+1.992
TTM-2.1535Y-11.394+9.241
5Y-11.39410Y-28.263+16.869
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.695-2.262+0.567
MRQ-1.753-2.599+0.846
TTM-2.153-2.674+0.521
YOY-4.145-4.133-0.012
5Y-11.394-6.258-5.136
10Y-28.263-6.171-22.092
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Hansa Biopharma AB:

  • The EOD is -1.958. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.025. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.379. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.958MRQ-2.025+0.067
MRQ-2.025TTM-2.379+0.354
TTM-2.379YOY-4.956+2.577
TTM-2.3795Y21.129-23.508
5Y21.12910Y-14.602+35.731
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.958-2.913+0.955
MRQ-2.025-3.275+1.250
TTM-2.379-3.508+1.129
YOY-4.956-5.620+0.664
5Y21.129-8.306+29.435
10Y-14.602-8.854-5.748
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Hansa Biopharma AB is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -4.10 means the investor is paying kr-4.10 for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of Hansa Biopharma AB:

  • The EOD is -3.961. Based on the equity, the company is expensive. -2
  • The MRQ is -4.096. Based on the equity, the company is expensive. -2
  • The TTM is -7.220. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.961MRQ-4.096+0.135
MRQ-4.096TTM-7.220+3.124
TTM-7.220YOY6.316-13.536
TTM-7.2205Y5.581-12.800
5Y5.58110Y15.205-9.624
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.9611.858-5.819
MRQ-4.0962.090-6.186
TTM-7.2202.091-9.311
YOY6.3162.866+3.450
5Y5.5813.488+2.093
10Y15.2053.836+11.369
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Hansa Biopharma AB compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---3.917-3.744-4%-1.050-73%-1.148-71%-0.178-95%
Book Value Per Share---7.105-2.003-72%8.754-181%10.741-166%8.343-185%
Current Ratio--2.5513.191-20%5.344-52%7.584-66%8.565-70%
Debt To Asset Ratio--1.4511.134+28%0.626+132%0.445+226%0.271+436%
Debt To Equity Ratio---1.620-100%2.012-100%0.841-100%0.476-100%
Dividend Per Share----0%-0%-0%-0%
Eps---4.150-4.010-3%-3.211-23%-2.769-33%-1.715-59%
Free Cash Flow Per Share---3.593-3.497-3%-2.777-23%-2.338-35%-1.472-59%
Free Cash Flow To Equity Per Share---3.628-3.533-3%2.538-243%-0.287-92%0.220-1751%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---110.366--------
Intrinsic Value_10Y_min---146.227--------
Intrinsic Value_1Y_max---6.646--------
Intrinsic Value_1Y_min---12.099--------
Intrinsic Value_3Y_max---23.331--------
Intrinsic Value_3Y_min---38.780--------
Intrinsic Value_5Y_max---44.072--------
Intrinsic Value_5Y_min---67.917--------
Market Cap1482184452.000-3%1532749380.0001753444222.000-13%2752364909.000-44%5339103342.900-71%6059771946.771-75%
Net Profit Margin---3.905-6.051+55%-5.515+41%-48.063+1131%-47.138+1107%
Operating Margin----4.6840%-5.1930%-47.8830%-36.3400%
Operating Ratio--3.7316.356-41%6.081-39%48.903-92%47.813-92%
Pb Ratio-3.961+3%-4.096-7.220+76%6.316-165%5.581-173%15.205-127%
Pe Ratio-1.695+3%-1.753-2.153+23%-4.145+136%-11.394+550%-28.263+1512%
Price Per Share28.140-3%29.10033.290-13%52.255-44%101.366-71%115.048-75%
Price To Free Cash Flow Ratio-1.958+3%-2.025-2.379+17%-4.956+145%21.129-110%-14.602+621%
Price To Total Gains Ratio-7.183+3%-7.429-9.437+27%-10.981+48%-41.793+463%-98.147+1221%
Quick Ratio--2.5473.160-19%5.448-53%9.740-74%11.376-78%
Return On Assets---0.263-0.196-26%-0.138-47%-0.146-45%-0.133-49%
Return On Equity----0.3450%-0.3850%-0.2410%-0.1890%
Total Gains Per Share---3.917-3.744-4%-1.050-73%-1.148-71%-0.178-95%
Usd Book Value---34389807.100-9697954.275-72%42375090.000-181%51993031.540-166%40386529.306-185%
Usd Book Value Change Per Share---0.360-0.344-4%-0.097-73%-0.105-71%-0.016-95%
Usd Book Value Per Share---0.653-0.184-72%0.805-181%0.987-166%0.767-185%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.381-0.369-3%-0.295-23%-0.254-33%-0.158-59%
Usd Free Cash Flow---17392902.100-16928025.950-3%-13443706.375-23%-11318932.425-35%-7124912.803-59%
Usd Free Cash Flow Per Share---0.330-0.321-3%-0.255-23%-0.215-35%-0.135-59%
Usd Free Cash Flow To Equity Per Share---0.333-0.325-3%0.233-243%-0.026-92%0.020-1751%
Usd Market Cap136212751.139-3%140859668.022161141524.002-13%252942335.137-44%490663597.213-71%556893041.908-75%
Usd Price Per Share2.586-3%2.6743.059-13%4.802-44%9.315-71%10.573-75%
Usd Profit---20087410.100-19411072.050-3%-15579761.050-22%-13408664.905-33%-8306960.470-59%
Usd Revenue--5144653.9003811115.975+35%3410386.025+51%1778370.685+189%933605.208+451%
Usd Total Gains Per Share---0.360-0.344-4%-0.097-73%-0.105-71%-0.016-95%
 EOD+2 -6MRQTTM+6 -25YOY+7 -245Y+8 -2310Y+7 -24

3.2. Fundamental Score

Let's check the fundamental score of Hansa Biopharma AB based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.695
Price to Book Ratio (EOD)Between0-1-3.961
Net Profit Margin (MRQ)Greater than0-3.905
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than12.547
Current Ratio (MRQ)Greater than12.551
Debt to Asset Ratio (MRQ)Less than11.451
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.263
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of Hansa Biopharma AB based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose29.560
Total1/1 (100.0%)



Latest Balance Sheet

Balance Sheet of 2024-03-31. Currency in SEK. All numbers in thousands.

Summary
Total Assets830,550
Total Liabilities1,204,759
Total Stockholder Equity-374,209
 As reported
Total Liabilities 1,204,759
Total Stockholder Equity+ -374,209
Total Assets = 830,550

Assets

Total Assets830,550
Total Current Assets658,206
Long-term Assets172,344
Total Current Assets
Cash And Cash Equivalents 541,465
Net Receivables 115,540
Inventory 1,201
Total Current Assets  (as reported)658,206
Total Current Assets  (calculated)658,206
+/-0
Long-term Assets
Property Plant Equipment 24,842
Long-term Assets Other 147,502
Long-term Assets  (as reported)172,344
Long-term Assets  (calculated)172,344
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities257,994
Long-term Liabilities946,765
Total Stockholder Equity-374,209
Total Current Liabilities
Short-term Debt 7,540
Accounts payable 62,662
Other Current Liabilities 151,334
Total Current Liabilities  (as reported)257,994
Total Current Liabilities  (calculated)221,536
+/- 36,458
Long-term Liabilities
Long term Debt 927,116
Capital Lease Obligations 20,006
Long-term Liabilities Other 909
Long-term Liabilities  (as reported)946,765
Long-term Liabilities  (calculated)948,031
+/- 1,266
Total Stockholder Equity
Total Stockholder Equity (as reported)-374,209
Total Stockholder Equity (calculated)0
+/- 374,209
Other
Cash and Short Term Investments 541,465
Common Stock Shares Outstanding 52,672
Current Deferred Revenue36,458
Liabilities and Stockholders Equity 830,550
Net Debt 405,657
Net Invested Capital 552,907
Net Working Capital 400,212
Property Plant and Equipment Gross 24,842
Short Long Term Debt Total 947,122



Balance Sheet

Currency in SEK. All numbers in thousands.

 Trend2024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-06-302012-12-312012-06-302011-12-312011-06-302010-12-312010-06-302009-12-312009-06-302008-12-31
> Total Assets 
44,866
39,212
38,147
46,736
37,801
53,258
40,896
70,353
65,798
57,513
50,777
0
75,615
0
54,311
54,555
256,676
239,920
224,088
204,005
181,220
158,774
310,672
266,150
228,821
194,917
680,415
647,433
603,892
569,988
944,821
898,032
817,806
735,355
664,236
539,486
459,773
1,526,448
1,434,496
1,310,728
1,218,292
1,092,266
1,012,808
889,499
784,929
1,381,009
1,687,406
1,499,687
1,362,523
1,171,048
1,018,041
830,550
830,5501,018,0411,171,0481,362,5231,499,6871,687,4061,381,009784,929889,4991,012,8081,092,2661,218,2921,310,7281,434,4961,526,448459,773539,486664,236735,355817,806898,032944,821569,988603,892647,433680,415194,917228,821266,150310,672158,774181,220204,005224,088239,920256,67654,55554,311075,615050,77757,51365,79870,35340,89653,25837,80146,73638,14739,21244,866
   > Total Current Assets 
7,699
2,736
1,800
10,209
1,422
16,920
2,908
32,428
21,379
11,029
1,924
0
26,510
0
11,950
11,789
211,665
195,321
178,296
159,750
135,594
105,338
256,982
212,597
173,185
134,146
624,182
587,583
543,493
490,660
866,220
763,025
767,516
685,771
615,743
492,240
414,324
1,482,145
1,393,387
1,270,955
1,159,613
1,036,035
942,342
821,822
720,256
1,319,334
1,604,704
1,393,424
1,234,953
1,024,317
855,151
658,206
658,206855,1511,024,3171,234,9531,393,4241,604,7041,319,334720,256821,822942,3421,036,0351,159,6131,270,9551,393,3871,482,145414,324492,240615,743685,771767,516763,025866,220490,660543,493587,583624,182134,146173,185212,597256,982105,338135,594159,750178,296195,321211,66511,78911,950026,51001,92411,02921,37932,4282,90816,9201,42210,2091,8002,7367,699
       Cash And Cash Equivalents 
5,917
95
612
9,459
222
12,222
1,157
27,828
18,966
9,139
90
0
25,216
0
10,152
7,082
209,110
192,628
175,683
58,145
33,731
53,965
213,588
118,356
65,021
25,896
581,078
100,092
60,105
54,060
439,441
339,929
342,076
259,359
181,697
149,159
148,378
1,238,188
1,139,362
1,016,686
901,391
768,614
651,342
519,136
517,203
1,215,282
1,496,179
1,286,820
1,102,514
908,176
732,060
541,465
541,465732,060908,1761,102,5141,286,8201,496,1791,215,282517,203519,136651,342768,614901,3911,016,6861,139,3621,238,188148,378149,159181,697259,359342,076339,929439,44154,06060,105100,092581,07825,89665,021118,356213,58853,96533,73158,145175,683192,628209,1107,08210,152025,2160909,13918,96627,8281,15712,2222229,459612955,917
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
99,935
99,955
49,983
39,990
90,995
104,932
104,975
34,983
474,957
474,073
429,343
418,746
419,301
420,651
420,805
419,397
327,747
251,797
237,978
238,144
238,060
238,038
238,051
237,619
234,612
99,269
0
0
0
0
0
0
0
000000099,269234,612237,619238,051238,038238,060238,144237,978251,797327,747419,397420,805420,651419,301418,746429,343474,073474,95734,983104,975104,93290,99539,99049,98399,95599,9350000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12,534
9,315
7,257
7,410
3,795
4,789
5,607
5,952
15,334
14,149
5,979
6,943
16,126
20,061
29,247
23,237
67,890
103,407
103,095
107,551
105,567
129,938
113,021
91,756
115,540
115,54091,756113,021129,938105,567107,551103,095103,40767,89023,23729,24720,06116,1266,9435,97914,14915,3345,9525,6074,7893,7957,4107,2579,31512,534000000000000000000000000000
       Other Current Assets 
1,783
2,641
1,188
750
1,201
4,699
1,751
4,600
2,412
1,890
1,834
0
1,294
0
1,798
4,707
2,555
2,693
2,613
1,670
1,908
1,390
3,404
3,246
3,232
3,275
8,121
12,534
9,315
7,257
8,033
3,795
4,789
5,607
14,649
15,334
14,149
5,979
15,783
16,126
20,061
29,247
53,139
67,890
103,407
103,095
1
58,346
59,381
47,515
21,543
0
021,54347,51559,38158,3461103,095103,40767,89053,13929,24720,06116,12615,7835,97914,14915,33414,6495,6074,7893,7958,0337,2579,31512,5348,1213,2753,2323,2463,4041,3901,9081,6702,6132,6932,5554,7071,79801,29401,8341,8902,4124,6001,7514,6991,2017501,1882,6411,783
   > Long-term Assets 
37,167
36,476
36,347
36,526
36,379
36,338
37,988
37,925
44,420
46,484
48,852
0
49,104
0
42,361
42,766
45,011
44,599
45,792
44,255
45,626
53,436
53,690
53,553
55,636
60,771
56,233
59,850
60,399
79,328
78,601
135,008
50,290
49,583
48,493
47,247
45,450
44,303
41,109
39,773
58,679
56,231
70,466
67,677
64,673
61,675
82,702
106,263
127,570
146,731
162,890
172,344
172,344162,890146,731127,570106,26382,70261,67564,67367,67770,46656,23158,67939,77341,10944,30345,45047,24748,49349,58350,290135,00878,60179,32860,39959,85056,23360,77155,63653,55353,69053,43645,62644,25545,79244,59945,01142,76642,361049,104048,85246,48444,42037,92537,98836,33836,37936,52636,34736,47637,167
       Property Plant Equipment 
141
122
114
465
406
371
313
256
199
157
115
0
257
0
1,283
1,396
1,407
1,320
2,182
2,077
2,151
2,097
2,570
2,919
3,208
3,701
3,976
4,032
5,123
5,605
5,876
19,840
17,360
16,086
15,144
14,037
12,693
11,199
9,700
8,891
28,535
26,788
45,784
39,566
37,273
35,010
35,836
33,917
31,632
29,227
27,073
24,842
24,84227,07329,22731,63233,91735,83635,01037,27339,56645,78426,78828,5358,8919,70011,19912,69314,03715,14416,08617,36019,8405,8765,6055,1234,0323,9763,7013,2082,9192,5702,0972,1512,0772,1821,3201,4071,3961,28302570115157199256313371406465114122141
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
22,049
21,705
40,328
39,528
81,970
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000081,97039,52840,32821,70522,049000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
40,369
0
40,421
0
0
0
36,898
0
0
0
36,327
0
0
0
36,554
0
0
0
33,749
33,769
33,571
33,395
33,197
33,199
32,930
33,497
33,348
33,210
32,757
33,104
31,410
30,882
30,144
29,443
28,761
28,111
27,400
26,665
46,866
72,346
95,938
117,504
135,817
0
0135,817117,50495,93872,34646,86626,66527,40028,11128,76129,44330,14430,88231,41033,10432,75733,21033,34833,49732,93033,19933,19733,39533,57133,76933,74900036,55400036,32700036,89800040,421040,36900000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
30,163
-1
0
1
1
-1
-1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000-1-1110-130,163000000000000000000000000000000
> Total Liabilities 
4,132
4,714
13,226
3,376
5,635
4,442
6,189
2,251
2,556
2,911
5,097
0
4,864
0
4,507
15,041
12,604
9,862
12,562
13,083
21,019
19,968
26,979
26,085
30,221
27,027
49,754
55,628
60,926
63,686
84,945
62,958
62,411
67,240
101,421
65,540
81,691
188,268
192,372
160,908
187,052
192,701
255,235
253,513
302,930
1,036,186
1,084,494
1,085,021
1,180,340
1,233,255
1,185,917
1,204,759
1,204,7591,185,9171,233,2551,180,3401,085,0211,084,4941,036,186302,930253,513255,235192,701187,052160,908192,372188,26881,69165,540101,42167,24062,41162,95884,94563,68660,92655,62849,75427,02730,22126,08526,97919,96821,01913,08312,5629,86212,60415,0414,50704,86405,0972,9112,5562,2516,1894,4425,6353,37613,2264,7144,132
   > Total Current Liabilities 
4,132
4,714
5,226
3,376
5,635
4,442
6,189
2,251
2,556
2,911
5,097
0
4,864
0
4,416
14,960
12,535
9,802
12,513
13,045
20,992
18,818
25,732
24,525
27,074
22,886
43,598
49,032
55,171
50,009
72,331
42,965
49,668
57,605
94,540
58,606
73,614
114,569
114,203
92,719
104,749
117,123
171,219
152,799
231,614
205,443
264,713
240,902
301,591
296,731
320,988
257,994
257,994320,988296,731301,591240,902264,713205,443231,614152,799171,219117,123104,74992,719114,203114,56973,61458,60694,54057,60549,66842,96572,33150,00955,17149,03243,59822,88627,07424,52525,73218,81820,99213,04512,5139,80212,53514,9604,41604,86405,0972,9112,5562,2516,1894,4425,6353,3765,2264,7144,132
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
519
0
0
0
39
5,040
41
41
42
42
43
44
44
38
27
18
0
0
0
0
101
5,938
26,646
33,606
4,632
3,852
4,751
4,782
4,415
3,270
3,870
3,777
6,888
6,953
7,003
7,083
7,165
7,211
7,257
7,304
7,503
7,540
7,5407,5037,3047,2577,2117,1657,0837,0036,9536,8883,7773,8703,2704,4154,7824,7513,8524,63233,60626,6465,9381010000182738444443424241415,040390005190000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
24,114
21,510
28,508
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000028,50821,51024,1140000000000000000000000000000000
       Accounts payable 
0
0
0
0
0
0
0
0
840
0
710
0
0
0
1,795
4,250
0
0
1,000
0
0
0
6,482
0
0
0
3,771
0
0
0
40,426
24,114
21,510
28,508
50,573
25,295
30,505
34,033
26,669
27,043
24,330
31,079
53,360
32,813
54,960
49,103
62,476
61,115
57,267
67,862
108,748
62,662
62,662108,74867,86257,26761,11562,47649,10354,96032,81353,36031,07924,33027,04326,66934,03330,50525,29550,57328,50821,51024,11440,4260003,7710006,4820001,000004,2501,795000710084000000000
       Other Current Liabilities 
4,132
4,714
5,226
3,376
5,635
4,442
6,189
2,251
1,716
2,911
355
0
4,864
0
2,582
856
12,494
9,761
11,471
13,003
20,949
18,774
19,122
24,487
27,047
22,868
39,827
49,032
55,171
50,009
106
37,027
23,022
23,999
39,016
54,754
68,863
109,787
-2
89,449
100,879
113,346
110,971
145,846
78,527
89,085
154,642
131,552
194,112
176,359
163,264
151,334
151,334163,264176,359194,112131,552154,64289,08578,527145,846110,971113,346100,87989,449-2109,78768,86354,75439,01623,99923,02237,02710650,00955,17149,03239,82722,86827,04724,48719,12218,77420,94913,00311,4719,76112,4948562,58204,86403552,9111,7162,2516,1894,4425,6353,3765,2264,7144,132
   > Long-term Liabilities 
0
0
8,000
0
0
0
0
0
0
0
0
0
0
0
91
81
69
60
49
38
27
1,150
1,247
1,560
3,147
4,141
6,156
6,596
5,755
13,677
12,614
19,993
12,743
9,635
6,881
6,934
8,077
73,699
78,169
68,189
82,303
75,578
84,016
100,714
71,316
830,743
819,781
844,119
878,749
936,524
864,929
946,765
946,765864,929936,524878,749844,119819,781830,74371,316100,71484,01675,57882,30368,18978,16973,6998,0776,9346,8819,63512,74319,99312,61413,6775,7556,5966,1564,1413,1471,5601,2471,15027384960698191000000000008,00000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,293
1,317
18,391
17,092
29,213
27,484
25,721
783,933
783,927
817,197
858,591
922,512
0
0
00922,512858,591817,197783,927783,93325,72127,48429,21317,09218,3911,3171,29300000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,596
5,755
13,677
12,138
10,705
5,613
3,547
2,054
2,223
5,428
72,254
77,539
67,607
64,658
59,186
55,525
73,991
46,376
46,810
35,854
26,922
0
0
0
0
000026,92235,85446,81046,37673,99155,52559,18664,65867,60777,53972,2545,4282,2232,0543,5475,61310,70512,13813,6775,7556,596000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
30,163
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000030,163000000000000000000000000000000
> Total Stockholder Equity
40,734
34,497
24,921
43,360
32,166
48,816
34,707
68,102
63,242
54,602
45,680
0
70,750
0
49,804
39,514
244,072
230,058
211,526
190,922
160,201
138,806
283,693
240,065
198,600
167,890
630,661
591,805
542,966
506,302
859,876
835,074
755,395
668,115
562,815
473,946
378,082
1,338,180
1,242,124
1,149,820
1,031,240
899,565
757,573
635,986
481,999
344,823
602,912
414,666
182,183
-62,207
-167,876
-374,209
-374,209-167,876-62,207182,183414,666602,912344,823481,999635,986757,573899,5651,031,2401,149,8201,242,1241,338,180378,082473,946562,815668,115755,395835,074859,876506,302542,966591,805630,661167,890198,600240,065283,693138,806160,201190,922211,526230,058244,07239,51449,804070,750045,68054,60263,24268,10234,70748,81632,16643,36024,92134,49740,734
   Common Stock
19,316
0
19,316
0
0
0
0
0
22,225
22,225
22,225
0
25,930
0
25,930
25,930
0
0
32,412
0
0
0
35,055
0
0
0
38,208
591,805
542,966
506,302
40,682
835,074
755,395
668,115
41,448
473,946
378,082
1,338,180
45,895
1,149,820
1,031,240
899,565
46,335
635,986
481,999
344,823
55,034
414,666
182,183
0
55,034
0
055,0340182,183414,66655,034344,823481,999635,98646,335899,5651,031,2401,149,82045,8951,338,180378,082473,94641,448668,115755,395835,07440,682506,302542,966591,80538,20800035,05500032,4120025,93025,930025,930022,22522,22522,2250000019,316019,316
   Retained Earnings 
6,523
0
-9,289
0
0
0
0
0
-16,466
-8,640
-17,562
0
11,127
0
-9,462
-20,187
0
0
-75,728
0
0
0
-186,857
0
0
0
-363,517
0
0
0
-611,491
0
0
0
-971,821
0
0
0
-1,311,671
0
0
0
-1,859,953
0
0
0
-2,471,087
0
0
0
-3,302,807
0
0-3,302,807000-2,471,087000-1,859,953000-1,311,671000-971,821000-611,491000-363,517000-186,857000-75,72800-20,187-9,462011,1270-17,562-8,640-16,46600000-9,28906,523
   Capital Surplus 0000000000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
14,895
34,497
14,895
43,360
32,166
48,816
34,707
68,102
57,483
41,017
41,017
0
33,694
0
33,336
33,771
244,072
230,058
254,842
190,922
160,201
138,806
435,495
240,065
198,600
167,890
955,970
591,805
542,966
506,302
1,430,685
835,074
755,395
668,115
1,493,188
473,946
378,082
1,338,180
2,507,900
1,149,820
1,031,240
899,565
2,571,191
635,986
481,999
344,823
3,018,952
414,666
182,183
-62,207
3,080,305
0
03,080,305-62,207182,183414,6663,018,952344,823481,999635,9862,571,191899,5651,031,2401,149,8202,507,9001,338,180378,082473,9461,493,188668,115755,395835,0741,430,685506,302542,966591,805955,970167,890198,600240,065435,495138,806160,201190,922254,842230,058244,07233,77133,336033,694041,01741,01757,48368,10234,70748,81632,16643,36014,89534,49714,895



Balance Sheet

Currency in SEK. All numbers in thousands.




Cash Flow

Currency in SEK. All numbers in thousands.




Income Statement

Currency in SEK. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue134,094
Cost of Revenue-64,828
Gross Profit69,26669,266
 
Operating Income (+$)
Gross Profit69,266
Operating Expense-860,139
Operating Income-790,873-790,873
 
Operating Expense (+$)
Research Development411,325
Selling General Administrative450,492
Selling And Marketing Expenses-1,678
Operating Expense860,139860,139
 
Net Interest Income (+$)
Interest Income27,992
Interest Expense-105,520
Other Finance Cost-31,440
Net Interest Income-108,968
 
Pretax Income (+$)
Operating Income-790,873
Net Interest Income-108,968
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-830,812-750,934
EBIT - interestExpense = -896,393
-830,812
-726,200
Interest Expense105,520
Earnings Before Interest and Taxes (EBIT)-790,873-725,292
Earnings Before Interest and Taxes (EBITDA)-780,135
 
After tax Income (+$)
Income Before Tax-830,812
Tax Provision-1,210
Net Income From Continuing Ops-855,935-832,022
Net Income-831,720
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses924,967
Total Other Income/Expenses Net-39,939108,968
 

Technical Analysis of Hansa Biopharma AB
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Hansa Biopharma AB. The general trend of Hansa Biopharma AB is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Hansa Biopharma AB's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Hansa Biopharma AB.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 32.62 < 33.36 < 40.50.

The bearish price targets are: 27.94 > 25.00 > 22.00.

Tweet this
Hansa Biopharma AB Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Hansa Biopharma AB. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Hansa Biopharma AB Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Hansa Biopharma AB.

Hansa Biopharma AB Daily Moving Average Convergence/Divergence (MACD) ChartHansa Biopharma AB Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Hansa Biopharma AB. The current adx is .

Hansa Biopharma AB Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Hansa Biopharma AB.

Hansa Biopharma AB Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Hansa Biopharma AB.

Hansa Biopharma AB Daily Relative Strength Index (RSI) ChartHansa Biopharma AB Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Hansa Biopharma AB.

Hansa Biopharma AB Daily Stochastic Oscillator ChartHansa Biopharma AB Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Hansa Biopharma AB.

Hansa Biopharma AB Daily Commodity Channel Index (CCI) ChartHansa Biopharma AB Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Hansa Biopharma AB.

Hansa Biopharma AB Daily Chande Momentum Oscillator (CMO) ChartHansa Biopharma AB Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Hansa Biopharma AB.

Hansa Biopharma AB Daily Williams %R ChartHansa Biopharma AB Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Hansa Biopharma AB.

Hansa Biopharma AB Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Hansa Biopharma AB.

Hansa Biopharma AB Daily Average True Range (ATR) ChartHansa Biopharma AB Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Hansa Biopharma AB.

Hansa Biopharma AB Daily On-Balance Volume (OBV) ChartHansa Biopharma AB Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Hansa Biopharma AB.

Hansa Biopharma AB Daily Money Flow Index (MFI) ChartHansa Biopharma AB Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Hansa Biopharma AB.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-04WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-28BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-31MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-06CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-27MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-01MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-15BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-11WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Hansa Biopharma AB Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Hansa Biopharma AB based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose29.560
Total1/1 (100.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Hansa Biopharma AB with someone you think should read this too:
  • Are you bullish or bearish on Hansa Biopharma AB? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Hansa Biopharma AB? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Hansa Biopharma AB

I send you an email if I find something interesting about Hansa Biopharma AB.


Comments

How you think about this?

Leave a comment

Stay informed about Hansa Biopharma AB.

Receive notifications about Hansa Biopharma AB in your mailbox!